Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927947 | 1.00 | ADRA1A (0.43) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL888246 | 0.89 | ADRA1A (0.41) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL21518900 | 0.86 | ADRA1A (0.45) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4812494 | 0.86 | ADRA1A (0.45) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL21518898 | 0.86 | ADRA1A (0.45) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL7075579 | 0.83 | PTGS2 (0.38) | ADRA1A | |
| SCHEMBL13381209 | 0.83 | ADRA1A (0.46) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL7978011 | 0.80 | GRM2 (0.44) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3702143 | 0.79 | ALDH1A1 (0.50) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL18922697 | 0.79 | MEN1 (0.41) | MEN1KMT2ATSHRCYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390825-B1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | OXA1L, OTC, ODC1 | ADRA1A 4214/4885CHRM2 4253/4885CHRM4 2848/4885 |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | OXA1L, OGFOD1, CYP51A1 | ADRA1A 3296/4885CHRM2 2508/4885CHRM4 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.